PTIX · Protagenic Therapeutics, Inc.\new · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“The Company does not have sufficient resources to fund its operations past twelve months from the date these consolidated financial statements are available to be issued. The Company expects that additional capital may be required during the next 12 months to continue executing its business plan and to meet its obligations as they become due. Accordingly, these conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.”View the 10-Q filed Aug 19, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-21 | ARMEN GARO H |
Director, Executive Chairman, 10% Owner |
Buy↑
|
COMMON STOCK
|
20,000 |
| 2026-08-20 | ARMEN GARO H |
Director, Executive Chairman, 10% Owner |
Buy↑
|
COMMON STOCK
|
16,634 |
| 2026-08-19 | ARMEN GARO H |
Director, Executive Chairman, 10% Owner |
Buy↑
|
COMMON STOCK
|
2,700 |
| 2026-08-11 | ARMEN GARO H |
Director, Executive Chairman, 10% Owner |
Buy↑
|
COMMON STOCK
|
2,220 |
| 2026-08-06 | ARMEN GARO H |
Director, Executive Chairman, 10% Owner |
Buy↑
|
COMMON STOCK
|
685 |
| 2026-08-05 | ARMEN GARO H |
Director, Executive Chairman, 10% Owner |
Buy↑
|
COMMON STOCK
|
5,000 |
| 2026-07-30 | ARMEN GARO H |
Director, Executive Chairman, 10% Owner |
Buy↑
|
COMMON STOCK
|
26,291 |
| 2024-03-25 | Stein Robert Benjamin |
President, Regenerative Med. |
Award↑
Filing footnotes — PTIX Common stock Options (Direct)
50,000 of the options are fully-exerciseable on March 25, 2026. The other 25,000 of the options are exercisable on and after the date upon which the company consummates a corporate partnership, if that occurs before December 31, 2026. If the company does not enter into a corporate partnership before December 31, 2026, then those 25,000 options are never exercisable. |
PTIX Common stock Options
|
75,000 |
| 2024-03-25 | Arrow Alexander K. |
Chief Financial Officer |
Award↑
|
PTIX Common stock Options
|
100,000 |
| 2024-03-25 | WRIGHT TIMOTHY R |
Director, Chief Executive Officer |
Award↑
|
PTIX Common stock Options
|
21,250 |
| 2024-03-25 | Barrage Khalil |
Director |
Award↑
|
PTIX Common stock Options
|
22,500 |
| 2024-03-25 | ARMEN GARO H |
Director, Executive Chairman, 10% Owner |
Award↑
|
PTIX Common stock Options
|
250,000 |
| 2024-03-25 | Corvese Brian |
Director |
Award↑
|
PTIX Common stock Options
|
43,750 |
| 2024-03-25 | Buell Jennifer |
Director |
Award↑
Filing footnotes — PTIX Common stock Options (Direct)
50,000 of the options are fully-exerciseable on March 25, 2026. The other 25,000 of the options are exercisable on and after the date upon which the company consummates a corporate partnership, if that occurs before December 31, 2026. If the company does not enter into a corporate partnership before December 31, 2026, then those 25,000 options are never exercisable. |
PTIX Common stock Options
|
75,000 |
| 2023-10-12 | Arrow Alexander K. |
Chief Financial Officer |
Buy↑
|
PTIX Common Stock
|
8,000 |
| 2022-05-18 | Arrow Alexander K. |
Chief Financial Officer |
Buy↑
|
PTIX Common Stock
|
8,000 |
| 2022-05-17 | Arrow Alexander K. |
Chief Financial Officer |
Buy↑
|
PTIX Common Stock
|
23,000 |
| 2021-06-03 | Arrow Alexander K. |
Chief Financial Officer |
Buy↑
|
PTIXW Common Stock 5-year warrants strike price $4.98
|
16,900 |
| 2021-06-02 | Arrow Alexander K. |
Chief Financial Officer |
Buy↑
|
PTIXW Common Stock 5-year warrants strike price $4.98
|
100 |
| 2021-05-27 | Arrow Alexander K. |
Chief Financial Officer |
Buy↑
|
PTIXW Common Stock 5-year warrants strike price $4.98
|
3,000 |
| 2021-05-26 | Barrage Khalil |
Director |
Award↑
Filing footnotes — PTIX Common stock NSO Options (Direct)
This exercise price was determined by the Board of Directors at a Board Meeting held May 26, 2021. This number of options was determined by the Board of Directors at a Board Meeting held May 26, 2021. The options are fully vested. |
PTIX Common stock NSO Options
|
180,000 |
| 2021-05-18 | Arrow Alexander K. |
Chief Financial Officer |
Buy↑
|
PTIXW Common Stock 5-year warrants strike price $4.98
|
12,000 |
| 2021-05-18 | Arrow Alexander K. |
Chief Financial Officer |
Buy↑
|
PTIXW Common Stock 5-year warrants strike price $4.98
|
18,000 |
| 2021-05-03 | Barrage Khalil |
Director |
Convert↓
Filing footnotes — PTIX Common stock Options (Direct)
Represents a cash exercise of stock options in which the reporting person paid the exercise price of such options in cash. No shares were sold by the reporting person in connection with this transaction. The options are fully vested. |
PTIX Common stock Options
|
45,000 |
| 2021-05-03 | Barrage Khalil |
Director |
Convert↑
Filing footnotes — Protagenic Therapeutics, Inc. Common Stock (Direct)
$532,500.00 was paid in cash by the reporting person as consideration for the aggregate option exercise. |
Protagenic Therapeutics, Inc. Common Stock
|
120,000 |
| 2021-05-03 | Barrage Khalil |
Director |
Convert↓
Filing footnotes — PTIX Common stock Options (Direct)
Represents a cash exercise of stock options in which the reporting person paid the exercise price of such options in cash. No shares were sold by the reporting person in connection with this transaction. The options are fully vested. |
PTIX Common stock Options
|
150,000 |
| 2021-05-03 | Barrage Khalil |
Director |
Convert↓
Filing footnotes — PTIX Common stock Options (Direct)
Represents a cash exercise of stock options in which the reporting person paid the exercise price of such options in cash. No shares were sold by the reporting person in connection with this transaction. The options are fully vested. |
PTIX Common stock Options
|
120,000 |
| 2021-05-03 | Barrage Khalil |
Director |
Convert↑
Filing footnotes — Protagenic Therapeutics, Inc. Common Stock (Direct)
$532,500.00 was paid in cash by the reporting person as consideration for the aggregate option exercise. |
Protagenic Therapeutics, Inc. Common Stock
|
45,000 |
| 2021-05-03 | Barrage Khalil |
Director |
Convert↓
Filing footnotes — PTIX Common stock Options (Direct)
Represents a cash exercise of stock options in which the reporting person paid the exercise price of such options in cash. No shares were sold by the reporting person in connection with this transaction. The options are fully vested. |
PTIX Common stock Options
|
45,000 |
| 2021-05-03 | Barrage Khalil |
Director |
Convert↑
Filing footnotes — Protagenic Therapeutics, Inc. Common Stock (Direct)
$532,500.00 was paid in cash by the reporting person as consideration for the aggregate option exercise. |
Protagenic Therapeutics, Inc. Common Stock
|
150,000 |
| 2021-05-03 | Barrage Khalil |
Director |
Convert↑
Filing footnotes — Protagenic Therapeutics, Inc. Common Stock (Direct)
$532,500.00 was paid in cash by the reporting person as consideration for the aggregate option exercise. |
Protagenic Therapeutics, Inc. Common Stock
|
45,000 |
| 2021-04-30 | Arrow Alexander K. |
Chief Financial Officer |
Buy↑
|
PTIX Common Stock
|
1,000 |
| 2021-04-29 | Arrow Alexander K. |
Chief Financial Officer |
Buy↑
|
PTIX Common Stock
|
1,000 |
| 2020-07-18 | Buell Jennifer |
Director |
Award↑
|
PTIX Common stock Options
|
145,000 |
| 2020-07-18 | Arrow Alexander K. |
Chief Financial Officer |
Award↑
|
PTIX Common stock Options
|
124,998 |
| 2020-02-21 | Arrow Alexander K. |
Chief Financial Officer |
Award↑
Filing footnotes — PTIX Common stock Options (Direct)
As this was an option grant, there was no cost to the recipient. |
PTIX Common stock Options
|
307,497 |
| 2020-02-21 | Barrage Khalil |
Director |
Award↑
|
PTIX Common stock Options
|
120,000 |
| 2020-02-21 | ARMEN GARO H |
Director, Executive Chairman, 10% Owner |
Award↑
|
PTIX Common stock Options
|
300,000 |
| 2020-02-21 | Stein Robert Benjamin |
President, Regenerative Med. |
Award↑
Filing footnotes — PTIX Common stock Options (Direct)
As this was an option grant, there was no cost to the recipient. |
PTIX Common stock Options
|
150,000 |
| 2020-02-21 | Silverman Joshua |
Director |
Award↑
|
PTIX Common stock Options
|
120,000 |
| 2020-02-21 | Corvese Brian |
Director |
Award↑
Filing footnotes — PTIX Common stock Options (Direct)
As this was an option grant, there was no cost to the recipient. |
PTIX Common stock Options
|
120,000 |